Experiences with

Castration

Participants will receive testosterone enanthate (500mg, intramuscularly) in 56-day cycles, alongside darolutamide and standard castration therapy. The study also examines safety, PSA progression, quality of life, and hormone kinetics.

The Phase 2 trial adds docetaxel to this adaptive approach, aiming to prolong the castration-sensitive phase of mCSPC and improve survival outcomes.

Furthermore, our findings lay the groundwork for further research into the involvement of ERα and ERβ in PCa that results in its castration stage, CRPC, and emphasises the significance of ER distribution in various study models.

Radiotherapy controls local disease, reduces symptoms, and may potentially delay castration resistance, warranting its consideration alongside systemic therapies in high-volume mHSPC." ...as you can imagine that "may potentially delay castration resistance" is quite interesting for us!

We are talking about sequential therapy in this case, triplet is a different story (and it's used in castration sensitive setting). https://www.curetoday.com/view/arpis-may-improve-survival-in-some-with-prostate-cancer

If it was just my PSA going up it would be one thing but my testosterone is also going up so have I become literally castration resistant since my T is going up despite being on Orgovyx , hence my testicles keep producing T?

We are talking about heavily pretreated castration resistant prostace cancers here...so not so easy! You can read more here below! https://www.claritypharmaceuticals.com/news/copper-67_sar-bispsma_updates/

https://prostatewarriors.com/2024/11/20/phase-iii-trial-for-metastatic-castration-resistant-prostate-cancer-of-an-ezh2-inhibitor/

I am a 68yr old guy who had a Rarp in August 23 for a Grade 5 T3a prostate cancer Jan this year my PSA started to rise setting of alarm bells with my Urologist further test and a PSMA PET scan confirmed Metastatic recurrence on lymph nodes and a rib I was put back on to monthly Degarelix Hormone therapy

His cancer is still castration sensitive. He has previously had a prostatectomy, followed by radiation, and a few years after that 6 months of Lupron (which he doesn't want to repeat). He is currently on no medication but PSA is rising.

I'm assuming switching ARI will likely not have a huge effect as it's all same/similar mechanism of action for cancer that's castration resistant now...? Pluvicto (if even possible to get)...provenge?

Evidence from HORRAD, STAMPEDE, and PEACE-1 shows improved local control, fewer genitourinary complications, and delayed castration resistance, though a clear overall survival benefit remains unproven.

Castration resistance? I have 2 options to think about: 1) to wait untill PSA reaches around 0.7 or more and than another PSMAPETC as I did before. 2)ADT+ Zytiga immediately and see what happens. Your opinions? Thank you all.

it targets two antigens at the same time (PSMA and STEAP-1), which should give good results since in castration resistance settings STEAP-1 is expressed by 85% of cancerous cells and PSMA is 100 times more expressed in cancerous cells.

So it's not a cure or a new therapy per se, but can be useful to delay castration resistance (or maybe even invert it, but the article does not talk about it).

Using data from nearly 5,000 patients, the study showed that APA+ADT outperformed enzalutamide, abiraterone, and ADT alone in overall survival (OS), time to castration resistance (TTCR), and PSA response.

CC-94676 or BMS-986365 is a highly selective AR degrade for castration resistant prostate cancer, the first good results were reported in January this year, but in September we will get more news at ESMO 2024 https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/presentation/list?

The study also highlighted that prolonged effective castration periods might increase oncological benefits in some patient cohorts, though these observations warrant further research for confirmation. https://www.sciencedirect.com/science/article/pii/S0302283824026010?dgcid=author

"" - horrible term - but when we reduce the testosterone this is the effect. When testosterone can be reduced by ADT then we say that the prostate cancer is "castration sensitive" or "hormone sensitive". We want to be sensitive as long as possible.

Sources ncbi.nlm.nih.gov favicon pmc.ncbi.nlm.nih.gov favicon cancer.gov favicon cancer.org favicon prostatecanceruk.org favicon View 5 more Answer Based on the available research, there is no definitive "best" supplement for castration-resistant prostate cancer (CRPC).